Vivotif® -: A 'magic shield' for protection against typhoid fever and delivery of heterologous antigens

被引:24
作者
Gentschev, Ivaylo
Spreng, Simone
Sieber, Heike
Ures, Jose
Mollet, Fabian
Collioud, Andre
Pearman, Jon
Griot-Wenk, Monika E.
Fensterle, Joachim
Rapp, Ulf R.
Goebel, Werner
Rothen, Simon A.
Dietrich, Guido
机构
[1] Berna Biotech Ltd, CH-3018 Bern, Switzerland
[2] Univ Wurzburg, Inst MSZ, Wurzburg, Germany
[3] Univ Wurzburg, Dept Microbiol, Wurzburg, Germany
关键词
live bacterial vaccines; Salmonella typhi Ty21a; Escherichia coli; haemolysin secretion system; vaccine carrier;
D O I
10.1159/000100515
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The attenuated Salmonella typhi strain Ty21a is the main constituent of Vivotif((R)), the only attenuated live oral vaccine against typhoid fever. In comparison with antibiotics, the 'magic bullets' which Paul Ehrlich was striving for to treat infectious diseases, this vaccine should be viewed as a 'magic shield', because rather than treating typhoid fever after the infection has started, immunisation with this vaccine strain prevents infection and disease by the induction of specific immune responses. Ty21a is also an attractive carrier for the delivery of heterologous antigens. Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:177 / 180
页数:4
相关论文
共 39 条
[21]  
LEVINE MM, 1990, LANCET, V336, P891
[22]  
LEVINE MM, 1989, REV INFECT DIS, V11, pS552
[23]  
LUNIN BS, 2000, INFECT IMMUN, V70, P5622
[24]  
Madhulika U, 2004, INDIAN J MED RES, V120, P111
[25]   Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers [J].
Metzger, WG ;
Mansouri, E ;
Kronawitter, M ;
Diescher, S ;
Soerensen, M ;
Hurwitz, R ;
Bumann, D ;
Aebischer, T ;
von Specht, BU ;
Meyer, TF .
VACCINE, 2004, 22 (17-18) :2273-2277
[26]   CLINICAL AND IMMUNOLOGICAL RESPONSE TO TYPHOID VACCINATION WITH PARENTERAL OR ORAL VACCINES IN 2 GROUPS OF 30 RECRUITS [J].
NISINI, R ;
BISELLI, R ;
MATRICARDI, PM ;
FATTOROSSI, A ;
DAMELIO, R .
VACCINE, 1993, 11 (05) :582-586
[27]   Vaccination against typhoid fever in travellers: a cost-effectiveness approach [J].
Papadimitropoulos, V ;
Vergidis, PI ;
Bliziotis, I ;
Falagas, ME .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (08) :681-683
[28]   Typhoid fever [J].
Parry, CM ;
Hien, TT ;
Dougan, G ;
White, NJ ;
Farrar, JJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (22) :1770-1782
[29]   Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors [J].
Pasetti, MF ;
Levine, MM ;
Sztein, MB .
VACCINE, 2003, 21 (5-6) :401-418
[30]   THE LIVE ORAL TYPHOID VACCINE TY21A IS A RPOS MUTANT AND IS SUSCEPTIBLE TO VARIOUS ENVIRONMENTAL STRESSES [J].
ROBBESAULE, V ;
COYNAULT, C ;
NOREL, F .
FEMS MICROBIOLOGY LETTERS, 1995, 126 (02) :171-176